DaVita (NYSE:DVA) Shares Gap Up Following Strong Earnings

DaVita Inc. (NYSE:DVA) shares gapped up before the market opened on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $111.19, but opened at $128.00. DaVita shares last traded at $136.6480, with a volume of 898,090 shares changing hands.

The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS.

DaVita News Summary

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 results beat expectations — DaVita posted ~ $3.29–$3.40 EPS (beat consensus) and revenue of $3.62B, up ~9.9% YoY, driven by steady dialysis demand and improved operating profit. DaVita Inc. 4th Quarter 2025 Results
• Positive Sentiment: Raised FY2026 guidance materially above Street — management set EPS guidance of $13.60–$15.00 vs. the prior consensus (~$12.80), signaling confidence in volume and pricing across its dialysis platform. DaVita forecasts 2026 profit above estimates
• Positive Sentiment: Shares reacted sharply in aftermarket trading after the print and guidance, reflecting strong investor appetite for the beat + upgrade. DaVita shares rise 7% as fourth quarter earnings, revenue beat estimates
• Neutral Sentiment: Analyst/market implications — company guidance exceeds many current sell‑side models (consensus cited lower), so estimates and targets may be revised higher; monitor analyst updates and revisions. MarketBeat DVA profile
• Negative Sentiment: Some underlying metrics deserve scrutiny — net income attributable to common shareholders fell YoY in the quarter and cash & cash equivalents declined; total liabilities rose year-over-year, which could limit flexibility. QuiverQuant Q4 financial details
• Negative Sentiment: Corporate ownership/activity — notable institutional moves (including reductions by large holders) and an eyebrow‑raising negative return-on-equity figure appear in the filings; investors should watch for follow-up commentary. QuiverQuant ownership & metrics

Wall Street Analyst Weigh In

DVA has been the subject of several recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. UBS Group reiterated a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Truist Financial reduced their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. Finally, TD Cowen reiterated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $148.60.

Institutional Trading of DaVita

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVA. NewEdge Advisors LLC lifted its holdings in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares during the period. Goldman Sachs Group Inc. increased its position in DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares during the last quarter. Truist Financial Corp raised its stake in DaVita by 1.9% during the second quarter. Truist Financial Corp now owns 8,646 shares of the company’s stock worth $1,232,000 after purchasing an additional 163 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in shares of DaVita by 485.5% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 44,809 shares of the company’s stock valued at $6,383,000 after purchasing an additional 37,156 shares during the last quarter. Finally, Ameritas Advisory Services LLC purchased a new stake in shares of DaVita during the 2nd quarter valued at $47,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

The firm has a market capitalization of $9.78 billion, a price-to-earnings ratio of 14.33, a P/E/G ratio of 0.67 and a beta of 0.99. The business has a fifty day moving average price of $113.42 and a 200 day moving average price of $124.86.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.